

# Tumor do Estroma Gastrointestinal (GIST)

## **Imatinibe**

Imatinibe: 400 mg/dia VO

Ref. (1)

Imatinibe: 400 mg VO BID

Ref. (2)

## **Sunitinibe**

Sunitinibe: 50mg/dia VO por 4 semanas a cada 6 semanas

Ref.(3)

## **Nilotinibe**

Nilotinibe: 400mg VO BID

Ref. (4)

1. Demetri GD, *et al.* Efficacy and safety of imatinib mesylate in advancedgastrointestinal stromal tumors. N Engl J Med 2002;347: 472–480.
2. Verweij J, Casali P *et al.* Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial Lancet 364:1127,2004.
3. Demetri GD *et al.*: Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumors after failure of imatinib: a randomized controlled trial. Lancet 368:1329, 2006.
4. Montemurro M, Schöffski P, Reichardt P, Gelderblom H, Schütte J, Hartmann JT, *et al.* Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib. Eur J Cancer. 2009 Sep; 45(13): 2293-7.